Alliancebernstein L.P. Has $2.30 Million Holdings in Esperion Therapeutics (ESPR)

Alliancebernstein L.P. boosted its stake in Esperion Therapeutics (NASDAQ:ESPR) by 40.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 34,970 shares of the biopharmaceutical company’s stock after purchasing an additional 10,000 shares during the period. Alliancebernstein L.P. owned about 0.13% of Esperion Therapeutics worth $2,302,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the business. Hamilton Lane Advisors LLC bought a new stake in shares of Esperion Therapeutics in the 4th quarter worth approximately $7,594,000. OxFORD Asset Management LLP bought a new stake in shares of Esperion Therapeutics in the 3rd quarter worth approximately $715,000. Ontario Teachers Pension Plan Board bought a new stake in shares of Esperion Therapeutics in the 4th quarter worth approximately $1,635,000. Schwab Charles Investment Management Inc. grew its position in shares of Esperion Therapeutics by 34.5% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 91,843 shares of the biopharmaceutical company’s stock worth $4,604,000 after buying an additional 23,568 shares during the last quarter. Finally, American Century Companies Inc. bought a new stake in shares of Esperion Therapeutics in the 4th quarter worth approximately $1,604,000. 91.66% of the stock is currently owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

NASDAQ ESPR opened at $66.43 on Friday. Esperion Therapeutics has a twelve month low of $30.95 and a twelve month high of $82.68. The company has a market cap of $1,830.57, a P/E ratio of -9.52 and a beta of 2.51.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported ($1.44) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.80) by $0.36. During the same period in the prior year, the business earned ($1.29) EPS. research analysts predict that Esperion Therapeutics will post -5.61 EPS for the current fiscal year.

In other Esperion Therapeutics news, Director Roger S. Newton sold 25,000 shares of the business’s stock in a transaction on Thursday, March 29th. The stock was sold at an average price of $72.37, for a total value of $1,809,250.00. Following the sale, the director now directly owns 639,682 shares of the company’s stock, valued at $46,293,786.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Nicole Vitullo sold 11,674 shares of the business’s stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $71.79, for a total value of $838,076.46. Following the completion of the sale, the director now directly owns 3,177 shares in the company, valued at $228,076.83. The disclosure for this sale can be found here. Insiders own 32.50% of the company’s stock.

ESPR has been the topic of a number of recent analyst reports. Stifel Nicolaus set a $105.00 price objective on Esperion Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, March 7th. Bank of America upgraded Esperion Therapeutics from a “neutral” rating to a “buy” rating and set a $76.00 price objective on the stock in a research report on Friday, January 5th. BidaskClub upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, December 16th. UBS set a $88.00 price objective on Esperion Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Finally, Deutsche Bank lifted their price objective on Esperion Therapeutics to $100.00 and gave the stock a “buy” rating in a research report on Friday, March 9th. Six analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Esperion Therapeutics presently has an average rating of “Buy” and a consensus price target of $92.54.

WARNING: This story was published by Ticker Report and is owned by of Ticker Report. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/3339982/alliancebernstein-l-p-has-2-30-million-holdings-in-esperion-therapeutics-espr.html.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Havven  Price Up 28% Over Last 7 Days
Havven Price Up 28% Over Last 7 Days
Head to Head Survey: Roper Technologies  & Mesa Laboratories
Head to Head Survey: Roper Technologies & Mesa Laboratories
Comparing PCM  & The Competition
Comparing PCM & The Competition
Brokerages Set $41.00 Price Target for Hutchison China MediTech Limited
Brokerages Set $41.00 Price Target for Hutchison China MediTech Limited
Logitech  Expected to Post Earnings of $0.26 Per Share
Logitech Expected to Post Earnings of $0.26 Per Share
Perrigo  Given a $105.00 Price Target by Canaccord Genuity Analysts
Perrigo Given a $105.00 Price Target by Canaccord Genuity Analysts


© 2006-2018 Ticker Report. Google+.